• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1997 Fiscal Year Final Research Report Summary

A tumor-associated antigen MN/G250 in urologic malignancies ; potetial therapeutic target

Research Project

Project/Area Number 08671834
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionNARA MEDICAL UNIVERSITY

Principal Investigator

HIRAO Yoshihiko  Dept.Urol.Nara Med.Univ.Professor, 医学部, 教授 (00133207)

Co-Investigator(Kenkyū-buntansha) OKAJIMA Eigoro  NARA MEDICAL UNIVERSTY Dept.Urol, Professor, 医学部, 名誉教授 (50075115)
UEMURA Hirotsugu  Dept.Urol.Nara Med.Univ.Assist Professor, 医学部, 講師 (90213397)
Project Period (FY) 1996 – 1997
KeywordsRenal cell carcinoma / MAbG250 / Anti-idiotype antibody / Immunotherapy / RT-PCR
Research Abstract

A murine monoclonal antibody MAbG250 is known to react with the majority of renal cell carcinomas (RCC) whereas reactivity with normal tissues is restricted to gastric mucosal cells and large blle duct cells. Recently, the G250 antigen has been identified (Oosterwijk et al.1995). Sequence analysis and database searching revealed that G250 antigen is identical to MN,a human tumor-associated antigen identified in cervical carcinoma (Pastorek et al, 1994). This antigen (G250, MN) is a transmembrane glycoprotein of 54 kDa and detectable in several types of malignancies but not in corresponding normal tissues. In the present study, we investigate MN/G250 expression with immunohistochemistry and RT-PCR in urologic cancers. MATERIAL & METHODS : Frozen specimens of bladder carcinoma (BT)(n=61), prostate carcinoma (PCa)(n=46), RCC (n=147) and germ cell tumor (GCT)(n=19)were studied for MN/G250 antigen peptide and gene expression. In addition, 17 RCC cell lines and 8 bladder carcinoma cell lines … More , and 3 PCa cell lines were studied. Cell lines were tested for MN/G250 expression by MHA and RT-PCR analysis with primers derived from cDNA sequence of MN/G250 antigen. RESULTS : In RCC,128/147 (87%) tissue specimens showed strong and homogeneous MN/G250 expression, in accordance with previous studies. Tumor grade and cell type appeared to correlate inversely with MN/G250 expression, i.e., high grade and sarcomatoid type showed significantly low expression as compared to the others. 6 of 17 (35%) RCC cell lines were G250 positive. In bladder carcinoma, 20/61(33%)primary tumors showed MN/G250 expression heterogeneously and 1/8(13%)cell lines were G250 positive. In contrast, no G250 expression was observed in PCa and GCT specimens and the other normal normal tissues.
Based, on these results describe above, we cariied out therapeutic experiments in mice with RCC xenograft. Briefly, small pieces of NUR-2 RCC were transplanted into the right flank of male nu/nu BALB/c mice. A couple of weeks after transplantation, mice were randomized and divided into each groups (n=6-7). Mice carrying NUR-2 human RCC xenografts (MN/G250^+,20mm^3) were treated by peri-tumor injection of MAbG250 and/or cytokines (m-IFN/IL-2/MCSF) or 0.2 ml of Ab3 sera with/without MCSF.Mice were treated 5 times a week for 6 weeks. Control mice were treated with 0.1 ml medium alone (RPMl 1640) or sera from MOPC21 immunized mice (Ab3-MOPC). The tumor-take rates and tumor growth were determined every week. RESULTS : All mice showed 100% tumor take after 4 weeks. However, the tumor volume in IFN or IL-2 therapy as well as MAbG250 treated animals were significantly lower as compared to control animals (p<0.01). Treatment with MCSF resulted in tumor growth inhibition but not significant. Combination of MAbG250 with cytokines resulted in increased anti-tumor effects as compared to MAbG250 or cytokine monotherapy. IL-2/IFN/MAbG250 therapy showed significant tumor growth Inhibition as compared to MAbG250 or cytokine monotherapy (p<0.05), however the other combination therapy were not significant. Moreover, Ab3-based (Ab2-induced) immunotherapy resulted in tremendous tumor growth inhibition as compared to MAbG250 or the other cytokine combination therapies (p<0.001).
CONCLUSIONS : Our findings suggest that MN/G250 antigen may be potential therapeutic target for RCC immunotherapy. Less

  • Research Products

    (14 results)

All Other

All Publications (14 results)

  • [Publications] 植村 天受: "腎細胞癌における抗イディオタイプ抗体の特異的免疫療法としての有用性" 奈良医学雑誌. 47. 76-87 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 植村 天受: "腎細胞癌における抗イディオタイプ抗体による特異的免疫療法の可能性" Biotherapy. 10. 241-244 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 植村 天受: "腫瘍抗原の内部イメージとしての抗イディオタイプ抗体" 臨床免疫. 28. 134-138 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 植村 天受: "腎細胞癌における抗体および抗イディオタイプ抗体による治療効果" Biotherapy. 11. 400-402 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 植村 天受: "腎細胞癌に対するMN targeting immunotherapyについて" Biotherapy. 12(in press). (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Uemura H: "Idiotypes in Medicine Autoimmunity,Intection & Concer" Elsevier Science, 540 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Hirao, Y., Uemura, H., Yoshida, K., Ozono, S., Okajima, E.: "Non-ichemic enucleation of small renal cell carcinoma using microwave tissue coagulator" Akuelle Urologie. 46. 17-19 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tsumatani, K., OZono, S., Uemura, H., Yamaguchi, H., Hirao, Y., Motomiya, Y., Okajima, E., Kitahori, Y., Hiasa, Y., Okabe, Y.: "Anti-tumor effect of vaccination with internal image anti-idiotype monoclonal antibodies." Biotherapy. 9. 294-295 (1995)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Uemura, H.and Okajima, E.: "Anti-idiotype antibody bearing the internal image of tumor-associated antigen." Clin.Immunol.Jan.28. 134-138 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Uemura, H.: "Potential tools for anti-idiotype anibodies for active specific immunotherapy in human renal cell carcinoma." J.Nara Med.Ass.47. 76-87 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Uemura, H., Okajima, E.and Oosterwijk, E.: "Possible tools for active specific immunotherapy with anti-idiotype antibodys in human renal cell carcinoma." Biotherapy. 10. 241-244 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Uemura, H., Ozono, S., Hirao, Y.and Okajima: "Effects of MAbG250 and Anti-idiotype antibody based immunotherapy in renal cell carcinoma." Biotherapy. 11. 400-402 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tsumattani, K., Nakagawa, Y., Kitahori, Y., Konishi, N., Uemura, H., Ozono, S., Hirao, Y., Okajima, E., Hirao, K., Hiasa, Y.: Toxicol.Pathol.25. 363-371 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Uemura, H., Nakagawa, Y., Ozono, Y., Hirao, Y., Okajima, E., Yoshikawa, K.: "MN targeting Immunotherapy for renal cell carcinoma" Biotherapy. 12(in press). (1998)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-03-16  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi